Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ispagel is a bulk-forming laxative developed by Bristol Laboratories, containing 3.5 g of ispaghula husk per sachet. As a natural fiber, ispaghula husk absorbs up to 40 times its own weight in water, which increases the bulk of the stools and physically encourages peristalsis to move waste through the digestive system. It is indicated for the relief of constipation, including during pregnancy, and for maintaining regularity in patients with irritable bowel syndrome (IBS), hemorrhoids, anal fissures, colostomies, and chronic diarrhea associated with diverticular disease or ulcerative colitis. The product is typically formulated as orange-flavored granules intended for oral suspension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ispagel.